Clinical trials: GIST
Sarcoma, Gastrointestinal Stromal Tumors
Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation
The presence of c-kit mutation is an independent poor prognostic factor for relapse in addition to large size (> 5 cm) and high mitotic rate (> 5/50 high power field [HPF]) in localized gastrointestinal stromal tumor (GIST)…
- Trial name
- NCT00278876
- Testing
- Imatinib mesylate (Glivec)
- Where
- 4 sites in South Korea
- Volunteers
- 47 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
This randomized phase II trial studies how well nivolumab with or without ipilimumab works in treating patients with gastrointestinal stromal tumor that has spread to other places in the body or cannot be removed by surgery.
- Trial name
- NCT02880020
- Testing
- Ipilimumab, Laboratory Biomarker Analysis, Nivolumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST)
This phase II trial studies the effect of rogaratinib in treating patients with sarcoma with a change in a group of proteins called fibroblast growth factor receptors (FGFRs) or SDH-deficient gastrointestinal stromal tumor…
- Conditions
- Locally Advanced Gastrointestinal Stromal Tumor, Locally Advanced Sarcoma, Metastatic Gastrointestinal Stromal Tumor, Metastatic Sarcoma
- Trial name
- NCT04595747
- Testing
- Biopsy Procedure, Biospecimen Collection, Computed Tomography
- Where
- 18 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Stromal Tumors, Small-cell Lung Cancer
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
- Conditions
- Gastrointestinal Stromal Tumors, Small-cell Lung Cancer, Adenoid Cystic Carcinoma, Uveal Melanoma
- Trial name
- NCT06805825
- Testing
- NN3201
- Where
- 5 sites in United States
- Volunteers
- 67 people
- Sponsor
- Novelty Nobility, Inc.
Biliary Tract Neoplasms, Gastric Cancer
Targeted Agent Evaluation in Digestive Cancers in China Based on Molecular Characteristics
This a prospective real-world navigation study using tumor DNA sequencing technology to sequence genes of previously treated and refractory gastrointestinal tumors, which are generally considered to be highly heterogeneous and…
- Conditions
- Biliary Tract Neoplasms, Gastric Cancer, Esophageal Squamous Cell Carcinoma, Colorectal Cancer
- Trial name
- VISIONARY (NCT04584008)
- Testing
- FGFR Inhibitor, IDH1 Inhibitor, HER2 Inhibitor, PARP Inhibitor, BRAF Inhibitor, MEK Inhibitor, ICIs, EGFR-TKIs, NTRK-TKI, and et. al., Other Therapy
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Peking University
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Cancer of Stomach, Oesophageal Cancer
The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
To determine the long term outcomes of Endoscopic Submucosal Dissection (ESD), Endoscopic Full Thickness Resection (EFTR) and Submucosal-Tunnelling Endoscopic Resection (STER) for upper gastrointestinal neoplastic lesions
- Conditions
- Cancer of Stomach, Oesophageal Cancer, Gastric Cancer, Gastric Adenocarcinoma
- Trial name
- ANZ UGI (NCT05804331)
- Where
- Australia
- Volunteers
- 500 people
- Sponsor
- Western Sydney Local Health District
Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors
Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib
In order to distinguish between clonal instability driven by imatinib in CML and actual changes with secondary clones induced by imatinib we would like to investigate the karyotype of non-CML patients treated with imatinib such…
- Conditions
- Chronic Myeloid Leukemia, Gastrointestinal Stromal Cell Tumors, Chromosome Abnormality
- Trial name
- GIST (NCT00461929)
- Testing
- bone marrow aspiration
- Where
- 2 sites in Canada
- Volunteers
- 68 people
- Sponsor
- University Health Network, Toronto
GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation
Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment
Gastrointestinal stromal tumors (GISTs) are mostly driven by c-kit or PDGFRA mutations, and commonly occur in the stomach and small intestine.
- Trial name
- NCT07559864
- Testing
- physician-selected treatment, Regorafenib + Envafolimab
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Jian Li
Gastrointestinal Stromal Tumors
A Cohort Study on the Safety of Laparoscopic Resection of 5cm or Larger Gastric Gastrointestinal Stromal Tumors
The purpose of this study is to explore the safety of laparoscopic resection of 5cm or larger gastric gastrointestinal stromal tumors
- Trial name
- NCT05938309
- Where
- China
- Volunteers
- 194 people
- Sponsor
- Fujian Medical University
Gastrointestinal Stromal Tumors
Current Management of Gastrointestinal Stromal Tumors (GIST) in the Region of Coquimbo
This is a retrospective analysis and description of the preferred diagnostic and treatment methods employed on GIST on the Region of Coquimbo from 2003 to 2008.
- Trial name
- NCT00564265
- Testing
- Observation
- Where
- Chile
- Volunteers
- 24 people
- Sponsor
- Cirujanos la Serena
Sarcoma
PTK787/ZK222584 in the Treatment of Metastatic Gastrointestinal Stromal Tumors Resistant to Imatinib
This study evaluates the safety and efficacy of a novel tyrosine kinase inhibitor, PTK787/ZK222584, in the treatment of GIST (gastrointestinal stromal tumor) that is resistant to imatinib mesylate (Gleevec).
- Trial name
- NCT00117299
- Testing
- PTK787/ZK222584
- Where
- Finland
- Volunteers
- 45 people
- Sponsor
- University of Helsinki
Cancer
Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005860
- Testing
- floxuridine, leucovorin calcium, oxaliplatin
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma, Non-small Cell Lung Cancer
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
The goal of this clinical research study is to learn how PLX3397 and pembrolizumab work together to affect cancer cells. PLX3397 is designed to target the receptor for CSF1 (CSF1R).
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Gastrointestinal Stromal Tumor (GIST)
- Trial name
- NCT02452424
- Testing
- PLX3397, Pembrolizumab
- Where
- 12 sites in United States
- Volunteers
- 78 people
- Sponsor
- Daiichi Sankyo
Gastrointestinal Stromal Tumors
WB-DWI for Early Prediction of Therapy Response in Patients With Advanced Metastatic GIST Treated With Regorafenib
The purpose of this study is to evaluate WB DWI as early predictor of response to treatment with regorafenib or placebo in patients with advanced metastatic GIST.
- Trial name
- NCT01265979
- Testing
- Whole body diffusion MRI
- Where
- Belgium
- Volunteers
- 5 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Gastrointestinal Stromal Tumor of Stomach
Robotic Resection for Patients With Gastric Gastrointestinal Stromal Tumors: a Single-center Study
Patients with gastric gastrointestinal stromal tumors will receive robotic resection.
- Trial name
- NCT03238820
- Testing
- Robotic gastric gastrointestinal stromal tumors resection
- Where
- China
- Volunteers
- 50 people
- Sponsor
- JIANG Zhi-Wei
Gastrointestinal Stromal Tumor
SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
The trial "The stop-GIST trial" is an Oslo University Hospital sponsored, prospective, open-label, 1-group, multicenter phase II trial evaluating discontinuation of imatinib in highly selected patients treated with imatinib…
- Trial name
- NCT02924714
- Testing
- Discontinuation of imatinib
- Where
- Norway
- Volunteers
- 31 people
- Sponsor
- Oslo University Hospital
Gastrointestinal Stromal Tumor(GIST)
Management of Imatinib-associated Severe Skin Rash in Patients With Gastrointestinal Stromal Tumor
To achieve optimal clinical outcomes with imatinib in GIST patients, it is crucial to maintain standard imatinib dose. Skin rash is a relatively common and sometimes severe adverse event of imatinib in GIST patients and may…
- Trial name
- NCT03440515
- Testing
- Prednisone
- Volunteers
- 29 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumors
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and…
- Trial name
- NCT05385549
- Testing
- Imatinib Mesylate
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Asan Medical Center
Gastrointestinal Stromal Tumor
Imatinib Mesylate With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor
This randomized phase III trial studies imatinib mesylate and bevacizumab to see how well they work compared to imatinib mesylate alone in treating patients with gastrointestinal stromal tumor that has spread to other parts of…
- Trial name
- S0502 (NCT00324987)
- Testing
- Bevacizumab, Imatinib Mesylate, Laboratory Biomarker Analysis
- Where
- 192 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- National Cancer Institute (NCI)